@adamfeuerstein / appears on tweets, tweets, tweets, tweets, tweets, tweets, tweets, tweets, tweets, tweets, tweets, tweets
No settled calls yet — credibility updates as call horizons resolve.
Sac-TMT, the $MRK Kelun Trop2-targeted ADC, wins again, this time topping the standard treatment for 1L PDL1-negative, non-squamous non-small cell lung cancer.
Sac-TMT, the $MRK Kelun Trop2-targeted ADC, wins again, this time topping the standard treatment for 1L PDL1-negative, non-squamous non-small cell lung cancer.
931 days. The drug approval scandal hiding in plain sight.
{
"type": "trace.speaker",
"handle": "adamfeuerstein",
"name": "Adam Feuerstein ✡️",
[
,
,
,
,
,
,
,
,
,
,
,
],
{
}
}AISO Market Calls classifies public statements from public sources. A classification such as long thesis, short thesis, or explicit call describes the content of the public statement and does not prove that the speaker actually entered, exited, or held a position. Market performance shown is calculated from public market data around the source publication or timestamp. It is not investment advice.
$BBIO Attruby sheds a competitor and the "stabilizer first" narrative get a boost.
$AZN $IONS Wainua ouch. Thanks for playing. You're out.
$ALNY Amvuttra, the silencer stands alone.
$VERA Trutakna approved for IgAN
The FDA adcomm for $REPL RP1 has been scheduled for July 30, according to a notice in the Federal Register.
That's one day after the $CAPR deramiocel adcomm on July 29.
Biotech is booming! The $XBI is close to its all-time high reached in February 2021.
No reach data yet.
Drop another platform link to enrich this profile. Drop a link →